KPI-121
Phase 3Small molecule
KPI-121 is one of 87 small molecule programs targeting Eye Disease. It is currently in Phase 3.
3
Indications
8
Total Trials
0
Active Trials
86
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
219 competitors in Cataract
#DrugCompanyPhaseTrials
1Pred Forte
NovartisPhase 3
Lotemax
BBausch & Lomb Incorporated
Phase 3
Toradol
JJavelin Pharmaceuticals
Phase 3
Kenalog
BBausch Health Americas, Inc.
Phase 3
Avastin
BBio-Thera Solutions
Phase 3
Isopto Carpine
AAdvanz Pharma
Phase 3
Intranasal Dexmedetomidine
BBaudax Bio
Phase 3
KPI-121
KKala Pharmaceuticals, Inc.
Phase 3
Ripasudil
KKowa Research Institute, Inc.
Phase 3
XG-102
XXigen SA
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Eye Disease3 trials
Safety and Efficacy3 trials
Diabetic Macular Edema1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for KPI-121. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- KKala Pharmaceuticals, Inc.